Molecular and clinical oncology最新文献

{"title":"Urinary metabolomic signatures associated with early adverse events during volumetric modulated arc therapy for prostate cancer: A secondary analysis of a public dataset.","authors":"Mai Fukushi, Yota Tatara, Hideki Obara, Satoru Monzen","doi":"10.3892/mco.2026.2953","DOIUrl":"10.3892/mco.2026.2953","url":null,"abstract":"<p><p>Volumetric modulated arc therapy (VMAT) is an advanced radiotherapy technique for prostate cancer that improves dose conformity but is often accompanied by early urinary toxicities. Non-invasive biomarkers for predicting such adverse events remain limited. In the present study, a secondary analysis of a public urinary metabolomics dataset (MxP^® Quant 500; 630 metabolites) from 11 patients treated with VMAT (76 Gy/38 fractions) was performed. Patients were grouped as patients with urinary toxicities (n=7; Grade 1) and those without (n=4). Patient-level Spearman's rank correlation coefficients (ρ) between the metabolite concentration and fraction number were calculated and summarized within each group. Overlaps in the top 60 positively correlated metabolites and bottom 60 negatively correlated metabolites across groups were identified and assessed using OmicsNet 2.0. Four metabolites [cholesteryl ester 20:4, taurodeoxycholic acid, triglyceride (TG) 18:0_32:2 and TG 18:3_34:1] were positively correlated in the toxicity group but negatively correlated in controls. Conversely, five metabolites, including phosphatidylcholines (PCs; PC aa C42:2 and PC ae C42:1), TG 16:0_38:1, fatty acid (FA) 20:2 and diglyceride 18:1_18:1, showed the opposite trend. Network analysis indicated impaired lipolysis, specifically the hydrolysis of TGs into FAs, involving carboxyl ester lipase and adipose TG lipase/hormone-sensitive lipase pathways. One patient with toxicity was on ursodeoxycholic acid, possibly influencing bile acid-related metabolites. Overall, early urinary adverse events in VMAT were associated with lipid metabolism dysregulation. No metabolites remained significant after false discovery rate correction, and this exploratory, hypothesis-generating analysis suggested that urinary metabolomics may serve as a non-invasive biomarker platform for toxicity prediction, warranting validation in larger cohorts.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"25 1","pages":"44"},"PeriodicalIF":1.9,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13172665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147964099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the value of the ovarian-adnexal reporting and data system combined with tumor markers in the differential diagnosis of benign and malignant ovarian-adnexal tumors.","authors":"Liyan Zhang, Li Xiao, Jiaxing Wang, Haiyan Wang","doi":"10.3892/mco.2026.2952","DOIUrl":"10.3892/mco.2026.2952","url":null,"abstract":"<p><p>To explore the value of the ovarian-adnexal reporting and data system (O-RADS) combined with tumor markers, risk of ovarian malignancy algorithm (ROMA) in the differential diagnosis of benign and malignant ovarian-adnexal tumors. A total of 426 patients with 524 cases of ovarian-adnexal tumors confirmed by surgery from January 2021 to January 2024 were included. Ultrasound O-RADS classification, ROMA and their combination were used for differential diagnosis. Taking pathological results as the gold standard, the sensitivity, specificity and the area under the receiver operating characteristic curves were calculated. Among the 524 tumors, there were 104 cases in category 2, 113 cases in category 3, 81 cases in category 4, 226 cases in category 5. The proportions of malignancy in O-RADS categories 2-5 were 0% (0/104), 4.42% (5/113), 53.09% (43/81) and 97.34% (220/226). Thus, it can be observed that the higher the ultrasound O-RADS classification, the higher the risk of malignancy. This was statistically significant. Taking O-RADS category 4 as the research objective, the patients were divided into two groups, pre-menopausal and post-menopausal for statistical analysis. Analysis revealed that the malignancy rate of postmenopausal O-RADS category 4 tumors was similar to that of O-RADS category 5. The risk of malignant tumors in postmenopausal women with O-RADS category 4 is significantly higher compared with that in premenopausal patients and the difference is statistically significant. The diagnostic efficacy of ROMA for benign and malignant tumors in postmenopausal patients was significantly greater when compared with premenopausal patients. When combined diagnosis is adopted, regardless of whether it is in the premenopausal or postmenopausal stage, the sensitivity and specificity of the diagnosis are significantly higher compared with those of a single diagnosis. Taking O-RADS category 4 as the research objective, the incidence of malignant tumors of O-RADS category 4 in postmenopausal women is similar to that of category 5. The diagnostic efficacy of ROMA for postmenopausal patients is greater when compared with that for premenopausal patients. The use of O-RADS classification combined with ROMA can improve the sensitivity and specificity for the differential diagnosis of benign and malignant ovarian-adnexal tumors.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"24 6","pages":"43"},"PeriodicalIF":1.9,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13158901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147931460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crosstalk between immune and programmed cell death and their application in colorectal cancer risk stratification.","authors":"Chaoqun Wu, Yueshuang Cai, Shao Chen, Yuelian Huang, Qiumei Wu","doi":"10.3892/mco.2026.2951","DOIUrl":"10.3892/mco.2026.2951","url":null,"abstract":"<p><p>Programmed cell death (PCD) and cellular immunity play pivotal roles in colorectal cancer (CRC) progression; understanding their crosstalk and identifying key genes could improve risk stratification and therapy. A univariate Cox analysis was performed to identify PCD-related genes (PRGs) and immune-related genes (IRGs) that are significantly associated with prognosis. Through principal component analysis (PCA), the immune and PCD levels were assessed in individual tumor tissues, subsequently categorizing patients into distinct molecular subtypes. Using the TCGA-COAD dataset as the training set and GSE17538 and GSE29621 as validation sets, machine learning model construction was performed. Leveraging the expression matrix of PRGs and IRGs, 101 machine learning models were constructed, with CoxBoost + Ridge emerging as the best-performing model. The model construction was based on previously reported methodology proposed, integrating 10 machine learning algorithms to form distinct models. The best model generated a risk score, referred to as the 'Score'. Additionally, the association between the 13 feature genes included in the Score and both prognosis and the tumor microenvironment (TME) were analyzed. Finally, experimental validation of the LTB4R gene was performed using western blotting and immunohistochemistry methods. In various datasets, PCA categorized patients into four molecular subtypes, with the immune potential index_low + PCD potential index_low group showing the highest survival rate. Among the 101 machine learning models developed, the CoxBoost + Ridge model demonstrated the best predictive performance. The Score generated by this model effectively stratified patients into high and low groups. Notably, significant differences were observed between the two groups in terms of TME, response to immunotherapy, and mutated genes. Additionally, a detailed analysis of the relationships between different feature genes, prognosis, and tumor immunity were conducted. In conclusion, the predictive model and risk score developed reflect the impact of the crosstalk between cellular immunity and PCD on the prognosis of CRC. Key genes in this crosstalk represent potential therapeutic targets, while our model provides a tool for TME evaluation and immunotherapy response prediction in CRC.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"24 6","pages":"42"},"PeriodicalIF":1.9,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13158725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147931422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in the clinical significance of CA125 for detecting progression among histological subtypes of epithelial ovarian carcinoma.","authors":"Kento Kato, Morikazu Miyamoto, Soko Nishimura, Risa Tanabe, Tsubasa Ito, Naohisa Kishimoto, Jin Suminokura, Yuka Otsuka, Taira Hada, Hiroaki Soyama, Kohei Omatsu, Yoshinobu Hamada, Masashi Takano","doi":"10.3892/mco.2026.2950","DOIUrl":"10.3892/mco.2026.2950","url":null,"abstract":"<p><p>Serum cancer antigen 125 (CA125) is the standard tool for surveillance of patients with epithelial ovarian carcinoma (OC). However, its utility may vary by histological subtype. The present study included patients with epithelial OC who completed primary therapy (surgery and chemotherapy) at the National Defense Medical College Hospital (Tokorozawa, Japan) between January 2006 and December 2022, achieved complete or partial response, and had a post-treatment CA125 level of <35 U/ml. Recurrence was defined using the Response Evaluation Criteria in Solid Tumors criteria via computed tomography (CT) imaging. Surveillance included quarterly CA125 testing for 5 years, and semiannual CT in year 1 followed by annual CT. All patients were classified into Group A, which included clear cell carcinoma and mucinous carcinoma, or Group B, which included high-grade serous carcinoma and other subtypes. Among 243 patients, there were 85 in Group A and 158 in Group B. First, the diagnostic performance of the standard CA125 cutoff (≥35 U/ml) for detecting recurrence was evaluated. The sensitivity was 28.6% in Group A and 81.8% in Group B; and the specificity was 98.4% in Group A and 98.8% in Group B. Second, because the sensitivity in Group A was very low, the CA125 ratio and a combined model (defined as CA125 ≥35 U/ml or CA125 ratio ≥1.5) were introduced. The CA125 ratio was defined as the maximum CA125 value measured at CT surveillance divided by the CA125 value measured just after the initial treatment for patients with CA125 <35 U/ml. The sensitivity was 66.7% in Group A and 93.5% in Group B; and the specificity was 84.1% in Group A and 86.4% in Group B. In conclusion, the utility of CA125 for the detection of recurrence differs substantially between histological subtypes, highlighting the need for histological subtype-specific surveillance strategies in epithelial OC.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"24 6","pages":"41"},"PeriodicalIF":1.9,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13158923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147931432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research advances in the role of circulating microorganisms in gastrointestinal tumors (Review).","authors":"Yang Yang, Yingzheng Ren, Tian Ma, Junjie An, Shuai Jin, Yonghong Dong","doi":"10.3892/mco.2026.2949","DOIUrl":"10.3892/mco.2026.2949","url":null,"abstract":"<p><p>Gastrointestinal tumors are common malignant tumors of the digestive system, which globally threaten human health. Notably, it has been discovered that blood and other circulating body fluids are not completely sterile; instead, they harbor complex and dynamic microbial DNA and signatures [circulating microorganisms (CM)]. These microorganisms primarily originate from the microbial translocation (including bacterial fragments, DNA and metabolites) through a compromised intestinal barrier, and are closely associated with the initiation and progression of gastrointestinal tumors, thus providing novel perspectives for early tumor diagnosis and prognosis. Although there is currently no evidence that CM can directly cause cancer, their metabolites and exosomes may contribute to tumor microenvironment remodeling. On one hand, they activate pattern recognition and inflammatory signaling pathways, such as Toll-like receptor/signal transducer and activator of transcription, potentially inducing and maintaining low-grade chronic inflammation. On the other hand, they may facilitate immune evasion, potentially promoting the 'inflammation-cancer' transition. With the development of metagenomic technologies and the maturation of next-generation high-throughput sequencing technologies, CM have shown potential as liquid biopsy biomarkers for the early diagnosis of gastrointestinal tumors. Interventions targeting specific CMs have also shown prospects for enhancing efficacy in early clinical trials. However, the field still faces numerous challenges, including insufficient depth of mechanistic validation and a lack of standardized detection protocols. Future efforts should aim to conduct further systematic research to clarify the biological functions and clinical translational value of CM in gastrointestinal tumors.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"24 6","pages":"40"},"PeriodicalIF":1.9,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13093237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147776215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in the molecular mechanisms and clinical applications of LEMD1 in tumor development and progression (Review).","authors":"Xiao-Bo Wang, Xian-Fei Wang, Sairah Binti Abdul Karim","doi":"10.3892/mco.2026.2948","DOIUrl":"10.3892/mco.2026.2948","url":null,"abstract":"<p><p>LAP2-emerin-MAN1 (LEM) domain-containing protein 1 (LEMD1), first identified in colorectal cancer in 2004, is a gene that is specifically expressed in the testis. The expression of LEMD1 is minimal in normal somatic cells but high in various types of malignant tumor (such as gastric, prostate, pancreatic and colorectal cancer as well as oral squamous cell carcinoma) due to abnormal promoter demethylation. LEMD1 promotes cell proliferation, invasion and metastasis during tumor progression, making it a potential diagnostic marker and therapeutic target. The present review summarized the research progress of LEMD1 as a cancer-testis antigen in tumor biology. Furthermore, the present review investigated the molecular structure and biological functions of LEMD1, its expression patterns, clinical relevance in various types of tumor, and highlighted current research challenges and future directions.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"24 6","pages":"39"},"PeriodicalIF":1.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13093238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147776210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two faces of Amitriptyline in an <i>in vitro</i> study on C6 glioma cells: The effects of Amitriptyline and its combination with Temozolomide and radiation.","authors":"Anna M Bielecka-Wajdman, Miłosz Gołyszny, Wojciech Majewski, Tomasz Cichoń, Krzysztof Szczepanik, Ewa Obuchowicz","doi":"10.3892/mco.2026.2947","DOIUrl":"10.3892/mco.2026.2947","url":null,"abstract":"<p><p>Failures in treating glioma have made it necessary to search for new therapies, especially those that have immunological properties. Amitriptyline (AMI) is not only used in the treatment of major depression but is also effective in the therapy for neuropathic and chronic cancer pain. Previous data have indicated anticancer and anti-inflammatory effects of AMI. However, at present, its effect on glioma cells in combination with the standard treatment, namely temozolomide (TEMO, the first-line cytostatic) and radiotherapy, has not been investigated. It would also be interesting to determine whether the mechanism of the immunomodulatory action of AMI is associated with its effect on the programmed death ligand-1 (PD-L1) expression, a key target for anticancer therapies. In the present study, the effect of AMI or its concomitant use with AMI and TEMO and/or radiation (10 Gy) on the viability, mortality (MTT, Trypan blue), proliferation (BrdU), colony forming (microscopic analysis) of C6 glioma cells and PD-L1 expression (enzyme immunoassay) was investigated. Although AMI induced the anticancer effects, it attenuated the effects of radiation. In radiated cell cultures, the combination of AMI and TEMO provoked the formation of larger glioma cell colonies and reversed the cellular effects of radiation. Moreover, AMI suppressed the expression of PD-L1 in cells that had been exposed to or had not been exposed to radiation, whereas radiation enhanced its expression. Because AMI exhibited promising anticancer properties including an interesting, previously unknown immunomodulatory effect, it appears that its potential therapeutic should be verified in an <i>in vivo</i> study.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"24 5","pages":"38"},"PeriodicalIF":1.9,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13077264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147691204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated microRNA-mRNA network analysis of invasive and immune-inflammatory pathways in sebaceous carcinoma of the eyelid with pagetoid spread.","authors":"Tatsuya Yunoki, Tetsushi Hirano, Yukihiro Furusawa, Yoshiaki Tabuchi, Atsushi Hayashi","doi":"10.3892/mco.2026.2946","DOIUrl":"10.3892/mco.2026.2946","url":null,"abstract":"<p><p>Pagetoid spread is a poor prognostic factor in sebaceous carcinoma (SGC) of the eyelid; however, its underlying molecular mechanisms remain unclear. The present study aimed to investigate the expression profiles of microRNAs (miRNAs/miRs) and mRNAs in SGC of the eyelid with pagetoid spread, compared with cases without pagetoid spread, and to explore potential miRNA-mRNA regulatory networks. Total RNA was extracted from three patients with SGC of the eyelid with pagetoid spread (pagetoid group), three patients without pagetoid spread (non-pagetoid group), and three patients with normal tarsal plate tissue obtained during free tarsal plate reconstruction (control group). Small RNA sequencing was performed using a next-generation sequencer to identify differentially expressed miRNAs among the groups, and bioinformatics analyses of mRNA expression profiles were conducted to determine associated biological functions and construct miRNA-mRNA interaction networks. In the pagetoid group, upregulated mRNAs and downregulated miRNAs were associated with enhanced invasion, migration and immune-inflammatory responses. Three miRNAs, miR-1275, miR-1976 and miR-330-5p, were commonly involved in these functional networks. Conversely, downregulated mRNAs and upregulated miRNAs were associated with impaired lipid metabolism, including miR-760-3p, miR-1266-5p, miR-3918, miR-1269a and miR-198. These findings suggest that SGC of the eyelid with pagetoid spread demonstrates increased invasive and migratory capacity, reduced lipid metabolic function and enhanced immune-inflammatory responses, which may contribute to its aggressive biological behavior.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"24 5","pages":"37"},"PeriodicalIF":1.9,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13077267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147691188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benefits and risks of prophylactic glucocorticoids in platinum chemotherapy for extensive-stage small-cell lung cancer: A retrospective study.","authors":"Wang Qingling, Wang Dafeng, Zhang Yan, Yan Xuebo","doi":"10.3892/mco.2026.2945","DOIUrl":"10.3892/mco.2026.2945","url":null,"abstract":"<p><p>The objective of the present study was to analyze the effects of prophylactic glucocorticoid use on the efficacy and adverse reactions of platinum-based intravenous regimens in patients with extensive-stage small-cell lung cancer (ES-SCLC). The present study retrospectively analyzed 103 newly diagnosed patients with ES-SCLC treated with etoposide plus platinum at the First Affiliated Hospital of Anhui Medical University from August 2022 to December 2024. Patients were divided into glucocorticoid (63 cases) and control (40 cases) groups. Baseline characteristics, adverse reaction rates and treatment outcomes were compared between groups. The hormone group showed no significant differences in objective response rate (ORR) and disease control rate (DCR) but had lower incidences of nausea/vomiting (P=0.005), constipation (P=0.002) and leukopenia (P=0.009). In patients also receiving immune checkpoint inhibitors (ICIs), the hormone group had improved renal function protection (P=0.026). Although hypertension incidence was higher in the hormone group, the difference was not statistically significant (P>0.05). Hyperglycemia rates and median survival time were similar between groups. In conclusion, prophylactic glucocorticoids do not significantly affect ORR, DCR, or median survival in patients with ES-SCLC on etoposide plus platinum with or without ICIs but can reduce nausea/vomiting, constipation and leukopenia. They may protect kidney function when combined with ICIs. No major adverse events were linked to glucocorticoid use, so their prophylactic use is recommended in platinum-based ES-SCLC therapy.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"24 5","pages":"36"},"PeriodicalIF":1.9,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13082824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147698566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling the mysteries of C1QBP in gynecological tumors (Review).","authors":"Hanrui Zhang, Jia Feng, Xidan Zhu, Fuyou Fu, Baolin Li, Tongtong Guo, Jinbo Liu, Ping Zhan","doi":"10.3892/mco.2026.2944","DOIUrl":"10.3892/mco.2026.2944","url":null,"abstract":"<p><p>The morbidity and mortality of gynecological tumors have been increasing globally in recent years. The identification of new biomarkers and drug targets has become an opportunity and challenge in the treatment of these tumor types. In recent years, the role of mitochondrial oxidative phosphorylation in the development of gynecological tumors has attracted attention, and existing studies have shown that complement component 1 Q subcomponent-binding protein (C1QBP) is involved in critical biological processes such as proliferation, migration and invasion of these tumors. However, the specific mechanism and function of C1QBP in gynecological tumors remain unknown and further studies are still needed to reveal its role and clinical application prospects. Therefore, the present review describes the changes and mechanism, such as in the apoptosis and invasion of tumor cells, of C1QBP in cervical, ovarian and endometrial cancer. The present review examines the current research progress on C1QBP in gynecological tumors to provide new ideas and methods for diagnosing and treating this disease.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"24 5","pages":"35"},"PeriodicalIF":1.9,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13040531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147609395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}